BioStock

Prenumeration

Alzinova secures short-term financing – CEO comments

2025-10-20 10:23:00

Alzinova is strengthening its financial position through a short-term loan agreement of SEK 11 million with two external lenders. The purpose is to secure working capital into the first quarter of 2026, while the company prepares for the next clinical phase with its Alzheimer’s vaccine candidate, ALZ-101. We spoke with CEO Tord Labuda for a comment on the background to the financing, the company’s priorities, and the road to phase II.

Read the full interview at biostock.se:

Alzinova secures short-term financing – CEO comments

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden